Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Receivables - Other: 2019-2025

Historic Receivables - Other for Bicycle Therapeutics (BCYC) over the last 6 years, with Sep 2025 value amounting to $67.3 million.

  • Bicycle Therapeutics' Receivables - Other rose 16.03% to $67.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $67.3 million, marking a year-over-year increase of 16.03%. This contributed to the annual value of $35.7 million for FY2024, which is 48.31% up from last year.
  • As of Q3 2025, Bicycle Therapeutics' Receivables - Other stood at $67.3 million, which was up 10.69% from $60.8 million recorded in Q2 2025.
  • Over the past 5 years, Bicycle Therapeutics' Receivables - Other peaked at $67.3 million during Q3 2025, and registered a low of $7.7 million during Q3 2021.
  • For the 3-year period, Bicycle Therapeutics' Receivables - Other averaged around $39.5 million, with its median value being $39.1 million (2024).
  • As far as peak fluctuations go, Bicycle Therapeutics' Receivables - Other decreased by 20.81% in 2023, and later surged by 260.47% in 2024.
  • Quarterly analysis of 5 years shows Bicycle Therapeutics' Receivables - Other stood at $10.9 million in 2021, then skyrocketed by 75.64% to $19.2 million in 2022, then grew by 25.45% to $24.0 million in 2023, then surged by 48.31% to $35.7 million in 2024, then increased by 16.03% to $67.3 million in 2025.
  • Its last three reported values are $67.3 million in Q3 2025, $60.8 million for Q2 2025, and $46.2 million during Q1 2025.